Literature DB >> 27357547

Role of scleraxis in mechanical stretch-mediated regulation of cardiac myofibroblast phenotype.

Patricia L Roche1, Raghu S Nagalingam1, Rushita A Bagchi1, Nina Aroutiounova2, Breanna M J Belisle2, Jeffrey T Wigle3, Michael P Czubryt4.   

Abstract

The phenotype conversion of fibroblasts to myofibroblasts plays a key role in the pathogenesis of cardiac fibrosis. Numerous triggers of this conversion process have been identified, including plating of cells on solid substrates, cytokines such as transforming growth factor-β, and mechanical stretch; however, the underlying mechanisms remain incompletely defined. Recent studies from our laboratory revealed that the transcription factor scleraxis is a key regulator of cardiac fibroblast phenotype and extracellular matrix expression. Here we report that mechanical stretch induces type I collagen expression and morphological changes indicative of cardiac myofibroblast conversion, as well as scleraxis expression via activation of the scleraxis promoter. Scleraxis causes phenotypic changes similar to stretch, and the effect of stretch is attenuated in scleraxis null cells. Scleraxis was also sufficient to upregulate expression of vinculin and F-actin, to induce stress fiber and focal adhesion formation, and to attenuate both cell migration and proliferation, further evidence of scleraxis-mediated regulation of fibroblast to myofibroblast conversion. Together, these data confirm that scleraxis is sufficient to promote the myofibroblast phenotype and is a required effector of stretch-mediated conversion. Scleraxis may thus represent a potential target for the development of novel antifibrotic therapies aimed at inhibiting myofibroblast formation.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  cardiac fibroblast; migration; proliferation; stretch; transcription factor

Mesh:

Substances:

Year:  2016        PMID: 27357547     DOI: 10.1152/ajpcell.00333.2015

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  10 in total

1.  miR-214 is Stretch-Sensitive in Aortic Valve and Inhibits Aortic Valve Calcification.

Authors:  Md Tausif Salim; Joan Fernández Esmerats; Sivakkumar Arjunon; Nicolas Villa-Roel; Robert M Nerem; Hanjoong Jo; Ajit P Yoganathan
Journal:  Ann Biomed Eng       Date:  2019-01-22       Impact factor: 3.934

2.  Targeting the renin-angiotensin-aldosterone system in fibrosis.

Authors:  Mohammad AlQudah; Taben M Hale; Michael P Czubryt
Journal:  Matrix Biol       Date:  2020-05-16       Impact factor: 11.583

Review 3.  Defining the Cardiac Fibroblast.

Authors:  Malina J Ivey; Michelle D Tallquist
Journal:  Circ J       Date:  2016-10-14       Impact factor: 2.993

Review 4.  Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps.

Authors:  Yonggang Ma; Rugmani Padmanabhan Iyer; Mira Jung; Michael P Czubryt; Merry L Lindsey
Journal:  Trends Pharmacol Sci       Date:  2017-03-29       Impact factor: 14.819

Review 5.  RAS inhibition in resident fibroblast biology.

Authors:  Alexandra M Garvin; Bilal S Khokhar; Michael P Czubryt; Taben M Hale
Journal:  Cell Signal       Date:  2020-12-25       Impact factor: 4.315

6.  Angiopoietin-like 4 induces a β-catenin-mediated upregulation of ID3 in fibroblasts to reduce scar collagen expression.

Authors:  Ziqiang Teo; Jeremy Soon Kiat Chan; Han Chung Chong; Ming Keat Sng; Chee Chong Choo; Glendon Zhi Ming Phua; Daniel Jin Rong Teo; Pengcheng Zhu; Cleo Choong; Marcus Thien Chong Wong; Nguan Soon Tan
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

7.  MicroRNA-30c suppresses the pro-fibrogenic effects of cardiac fibroblasts induced by TGF-β1 and prevents atrial fibrosis by targeting TGFβRII.

Authors:  Juan Xu; Haiqing Wu; Songwen Chen; Baozhen Qi; Genqing Zhou; Lidong Cai; Liqun Zhao; Yong Wei; Shaowen Liu
Journal:  J Cell Mol Med       Date:  2018-03-13       Impact factor: 5.310

8.  The Transcription Factor SCX is a Potential Serum Biomarker of Fibrotic Diseases.

Authors:  Miguel Ramírez-Aragón; Fernando Hernández-Sánchez; Tatiana S Rodríguez-Reyna; Ivette Buendía-Roldán; Gael Güitrón-Castillo; Carlos A Núñez-Alvarez; Diego F Hernández-Ramírez; Sergio A Benavides-Suárez; Alexia Esquinca-González; Ana Lilia Torres-Machorro; Criselda Mendoza-Milla
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 9.  Cardiac Fibroblast to Myofibroblast Phenotype Conversion-An Unexploited Therapeutic Target.

Authors:  Michael P Czubryt
Journal:  J Cardiovasc Dev Dis       Date:  2019-08-16

Review 10.  Canadian Contributions in Fibroblast Biology.

Authors:  Danah S Al-Hattab; Sikta Chattopadhyaya; Michael P Czubryt
Journal:  Cells       Date:  2022-07-23       Impact factor: 7.666

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.